|
|
 |
|
Viewing report
|
|
|
|
Special Report: Key Pricing and Reimbursement Trends for CNS Drugs
Decision Resources, Inc., July 2008, Pages: 86
Drugs for disorders of the central nervous system (CNS) form the second-ranked therapeutic area in terms of global pharmaceutical sales, reaching total retail sales in 2006 of $73.4 billion—equivalent to 19% of total pharmaceutical sales. However, pharmaceutical companies are subject to intense pressure from payers to moderate their prices. Additionally, physicians and patients face ever-more-daunting reimbursement barriers
Our analysis of the five-year pricing trend for 40 best-selling CNS therapies (20 neurology drugs and 20
psychiatric agents) shows that prices generally rise steadily in the United States but typically remain stable or decline in other major markets
Get the Answers You Need to Shape Your Strategy
- From 2003 to 2007, the U.S. prices of a sample of 20 best-selling neurology drugs increased by an average of 44%. Which other major market saw an increase in average prices for neurology drugs over this period? How did prices in this therapeutic area evolve in other markets?
- From 2003 to 2007, the U.S. prices of a sample of 20 leading psychiatric drugs increased by an average of 33%. What were the pricing trends for psychiatric drugs in other markets over this period? How did the expiration of patents on several blockbuster agents affect overall pricing trends for psychiatric drugs?
- Leading pharmacy benefit management companies (PBMs) in the United States report very varied spending trends for best-selling CNS drug classes in 2007. Which drug classes experienced strong growth in utilization and average prescription costs? Which drug classes underwent a decline in average prescription costs?
- The U.K. government has recently announced plans to reform its pharmaceutical pricing system and to implement a new constitution for the National Health Service. How will the reforms affect drug prices in the United Kingdom? What will the government do to promote pharmaceutical innovation?
Scope
- Geographic pricing trends: price evolution from 2003 to 2007 of 20 best-selling neurology drugs and 20 leading psychiatric agents in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan
- Drug class pricing trends: price evolution from 2003 to 2007 of leading antiepileptic drugs, antidementia drugs, Parkinson’s disease therapies, triptans, multiple sclerosis therapies, antidepressants, antipsychotics, and treatments for attention-deficit/hyperactivity disorder
- Reimbursement trends in major markets: leading PBMs’ CNS drug benefit trends in the United States; promoting increased use of generics in France; prescribing quotas for certain drug classes in Germany; new pharmaceutical budget in Italy; amendments to the Spanish reference pricing system;
price cuts in the United Kingdom; latest biennial price revisions in Japan
- Outlook and implications for the pharmaceutical industry: contrasting pricing trends in the United States and other major markets; lower price sensitivity in the biologics and neurology markets; impact of blockbuster patent expiration and generics competition; rebate trends in the United States; use of reference pricing in Europe; price cuts in some major markets.
Customers who bought this item also bought
The Pricing and Reimbursement Environment for Neurology Drugs
2008 Chartbook of International Pharmaceutical Prices
Pricing and Reimbursement Issues in Neurology
Pricing and Reimbursement of Fixed-Dose Combination Drugs in the United States
Special Report: 2009 Chartbook of International Pharmaceutical Prices
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
Pain Therapeutics - Drugs, Markets and Companies
Pricing and Reimbursement Environment for Immune Disease Therapies
Psychiatric Drugs: New Developments and Market Analysis by Drug Class and Clinical Indication
Commercial Insight: CNS Market Overview - Commercial Dynamics And Outlook Of The Neurology, Pain And Psychiatry Market Sectors
Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
Anti-Obesity Drugs - Trends & Opportunities Worldwide
|
|
|
|
